Siga announced a new contract with the U.S. Department of Defense, or DOD, for the procurement of approximately $9M of Tpoxx. This award is comprised primarily of oral Tpoxx, with a small amount of intravenous Tpoxx, and represents the third procurement contract award from the DOD over the past three years. Siga has been collaborating with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop the Post-exposure Prophylaxis indication for oral Tpoxx, and this work has been supported by a development contract with a value of approximately $27M as well as a Cooperative Research and Development Agreement. Inclusive of this award, Siga currently has approximately $154M of outstanding oral and IV Tpoxx orders, of which more than 85% of this amount was generated within the past three months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGA:
- Biotech Alert: Searches spiking for these stocks today
- Unusually active option classes on open August 16th
- Cisco, Walmart report quarterly earnings beats: Morning Buzz
- Siga slides, GeoVax jumps after mpox study shows limited effectiveness
- Siga Technologies falls 37% to $7.58 after mpox study failure